6 views
# The decline in cardiovascular diseases # :::warning Una sa lahat, ang mga Beta-blocker ay karaniwang ibinibigay sa mga pasyente na may heart failure, aortic aneurysm, pagkatapos ng myocardial infarction, at sa mga kababaihan na nasa edad ng pagbubuntis, lalo na sa mga kababaihang nagpaplano ng pagbubuntis. Madalas matanggap ng katawan ang Beta-blocker, pero maaari rin itong magdulot ng pantal sa balat at bradycardia – sobrang bagal ng tibok ng puso. ::: [![](https://cardio-balance-ph.store-best.net/img/9.jpg)](https://cardio-balance-ph.store-best.net) <div style="height:500px;"></div> ## Characteristics of diseases of the cardiovascular System ## <div class="alert alert-info" role="alert"> Ang pagkontrol sa presyon ay isang napakahalagang gawain, dahil ang pag-inom ng mga tableta na nakakatulong sa pagpapanatili ng normal na mga indikador ay maaaring magbigay ng araw-araw na komportableng buhay, upang maiwasan ang panganib ng hypertensive crisis, atake sa puso, at stroke. Ang mga gamot para sa kontrol ng presyon ay medyo malawakang makukuha sa mga botika, pero tanging ang doktor lang ang makakapili ng tamang gamot na angkop sa therapy. Lahat ng grupo ng gamot para pababain ang presyon ay may iba't ibang mekanismo ng epekto, side effects, at may kaunting posibilidad ng pagkadepende. Ang tamang pagpili ng gamot ay nagbibigay ng mabilis at tuloy-tuloy na resulta, at ang eksperimento sa sarili sa pag-inom ng gamot ay may mataas na posibilidad ng biglaang karamdaman, sakit sa puso at daluyan ng dugo, at sa matinding kaso, maaaring magdulot ng kamatayan. </div> The decline in cardiovascular diseases: causes and prospects In the last few decades, there has been in many developed countries, a significant decline in mortality due to cardiovascular disease (CVD). This Trend is the result of a combination of medical advances, preventative measures, and social changes. One of the most important factors for the reduction of CVD mortality, the improvement of diagnostic and therapeutic methods. The development of effective drugs — such as statins to lower cholesterol, antihypertensive drugs to control blood pressure, as well as anticoagulants for the prevention of thrombosis has improved the prognosis for patients with cardiovascular risk factors. In addition, invasive procedures such as coronary angiography, Percutaneous Coronary Intervention (PCI) and coronary Bypass surgery have revolutionized the treatment of acute heart attacks and coronary heart disease. Another important aspect is the prevention. Health campaigns aimed at the reduction of risk factors, play a Central role. These risk factors include: Smoking unhealthy diet, lack of physical activity, Overweight and obesity, chronically elevated blood pressure (hypertension), Diabetes mellitus. Through public awareness and political measures (such as tobacco tax increases, Werarkungsstandards and promotion of sports offered) could be reduced in many regions, the prevalence of these risk factors. For example, studies show that the number of smokers in Europe has decreased in the last 30 years, significant, which has directly contributed to the reduction of heart attacks and strokes. In addition, it has spread the awareness for a healthy way of life. The introduction of Screening programmes for the early detection of hypertension, hypercholesterolemia and Diabetes, and allows for early Intervention and thus prevention of serious consequences. Despite these positive developments, challenges remain, however. In some population groups, particularly in socially disadvantaged strata of society, the incidence of CVD remains high. In addition, the prevalence of obesity and Diabetes in some regions, continue to rise, which could threaten the long-term progress in the reduction of CVD. In summary, one can say that the decline in cardiovascular disease is due to a combination of medical advances, more effective prevention and social awareness. In order to secure this positive development in the long term, however, continuous investments in research, health promotion and social equality is required. Would you like me to make a certain section in more detail or additional aspects into account? > Cardio Balance is formulated and made after years of rigorous research and clinical study of the ingredients. The unique combination of each ingredient brings out optimal effectiveness in supporting heart and blood pressure. ![](https://cardio-balance-ph.store-best.net/img/9.jpg) <a href="https://hdoc.csirt-tooling.org/s/l4rLhOzTS1">The decline in cardiovascular diseases</a> Una sa lahat, ang mga Beta-blocker ay karaniwang ibinibigay sa mga pasyente na may heart failure, aortic aneurysm, pagkatapos ng myocardial infarction, at sa mga kababaihan na nasa edad ng pagbubuntis, lalo na sa mga kababaihang nagpaplano ng pagbubuntis. Madalas matanggap ng katawan ang Beta-blocker, pero maaari rin itong magdulot ng pantal sa balat at bradycardia – sobrang bagal ng tibok ng puso. <a href="https://pad.hxx.cz/s/CK89U2RYgW">Presyong pang-promosyon</a> ## Death from cardiovascular disease ## Cardiovascular disease: Protect your heart in time! Each year, cardiovascular challenge‑disorders of countless lives — often preventable. You don't leave the fate of the random: prevention starts today! Our comprehensive prevention program helps you to detect risk factors at an early stage and to reduce a targeted manner. With the most modern methods of investigation, individual consultations and tailor-made training plans, we can help you to keep your heart healthy. What you get: Regular Blood Pressure Checks Cholesterol and blood sugar Screening Personalized Nutrition Advice Heart Healthy Exercise Program Stress Management Techniques Call to Action: Sign up today for a free initial consultation! Call us at: Or visit our Website: https://cardio.nashi-veshi.ru Under the line: Your heart is unique, and treat it accordingly. Invest in your health before it is too late. <a href="https://md.infs.ch/s/KwZbtbvS0Q">Characteristics of diseases of the cardiovascular System</a> ** The decline in cardiovascular diseases **. Of course! Here is a scientific Text on the topic of characteristics of diseases of the cardiovascular system is set to English: Characteristics of diseases of the cardiovascular system He is the Central health challenges in modern societies include diseases of the cardiovascular system (HKS), one of the leading causes of death worldwide. Their early detection is based on the knowledge of the typical clinical and para-clinical characteristics. Clinical Symptoms The clinical signs of HKS diseases are diverse and can vary according to the affected structure. Among the most common symptoms: Angina pectoris: typical chest pain or Tightness, often retrosterbral localized, occurring during physical exertion and rest or sublingual administration of Nitroglycerin decay. Dyspnea: shortness of breath, especially on exertion (dyspnea on exertion) or at rest (orthopnea), may indicate congestive heart failure. Palpitations: perceived racing heart or irregular heartbeats, which are due to arrhythmias (e.g., atrial fibrillation). Edema, especially in the legs (peripheral Edema), or in the area of the lungs (pulmonary Edema), often a sign of a right‑ or left ventricular heart failure. Fatigue and impaired performance: General fatigue, and diminished capacity as a result of a reduced cardiac output. Syncope: a short-term loss of consciousness, due to a reduced cerebral blood flow (e.g., due to arrhythmic events or aortic stenosis). Para-clinical and objective findings In addition to the subjective complaints, objective findings, and laboratory and imaging parameters play a crucial role: Changes in blood pressure: hypertension (blood pressure ≥140/90 mmHg) or hypotension as a possible consequence or cause of HKS disorders. Abnormalities in the cardiac auscultation: heart sounds (e.g., valvular), rhythm disturbances or changes in heart Toni tensitäten. ECG changes: ST‑Segment elevation or depression, T‑wave inversions, arrhythmias or signs of hypertrophic ventricular wall. Echocardiographic findings: structural changes (ventricular hypertrophy, Valvular, chamber dilatation) and dysfunction (reduced ejection fraction). Laboratory parameters: Increased levels of cardiac enzymes such as Troponin (an indicator of myocardial necrosis), BNP (biological Marker of congestive heart failure), or lipid spectrum (a risk factor for atherosclerosis). Imaging procedures: coronary angiography for the depiction of stenosis in the coronary CT or MRI vessels, for the assessment of vascular changes or heart structures. Risk factors predisposing characteristics Many diseases of the HKS are associated with modifiable and non-modifiable risk factors: Modifiable: hypertension, hyperlipidemia, Diabetes mellitus, Smoking, Obesity, lack of physical activity, unhealthy diet. Non-modifiable: age, gender (higher risk for men in the middle ages), family history of early cardiovascular events. Conclusion The characteristics of cardiovascular diseases include a wide spectrum of clinical symptoms, objective findings, and risk profiles. A systematic collection of these characteristics allows early diagnosis and adequate therapy, which may improve the prognosis of the Affected significantly. Preventive measures for the modification of risk factors play a Central role in the reduction of the burden of disease. If you want, I can make certain sections in more detail, or other aspects add! - [x] <a href="https://hd.platypwnies.de/s/9xBlzcbE-W">Characteristics of diseases of the cardiovascular System</a> - [x] <a href="https://hack.utopia-lab.org/s/MbzXWZaVk">Death from cardiovascular disease</a> - [x] <a href="https://pad.stuve.de/s/9Lzd-ylCla">Hypertension of vsd</a> - [x] <a href="https://md.globenet.org/s/sSwjlYn0j">https://md.globenet.org/s/sSwjlYn0j</a> <a href="https://md.softwarefreedom.net/s/Gc_1BqshD">https://md.softwarefreedom.net/s/Gc_1BqshD</a> <a href="https://notes.simeonreusch.com/s/xxYpfCZNK">https://notes.simeonreusch.com/s/xxYpfCZNK</a> <a href="https://doc.gnuragist.es/s/98aehybnv9">https://doc.gnuragist.es/s/98aehybnv9</a> <a href="https://pads.cantorgymnasium.de/s/RFy9g5Adc">https://pads.cantorgymnasium.de/s/RFy9g5Adc</a> <a href="https://hedgedoc.private.coffee/s/Ox7Ol3dxW">https://hedgedoc.private.coffee/s/Ox7Ol3dxW</a> <a href="https://md.mandragot.org/s/pjg5FJ_TUJ">https://md.mandragot.org/s/pjg5FJ_TUJ</a> <a href="https://doc.fsr.saarland/s/wxNvWUN-cj">https://doc.fsr.saarland/s/wxNvWUN-cj</a> <a href="https://hedgedoc.ichmann.de/s/aGHGxsfvUx">https://hedgedoc.ichmann.de/s/aGHGxsfvUx</a> <a href="https://pad.cttue.de/s/Bi22l7sgP">https://pad.cttue.de/s/Bi22l7sgP</a> <a href="https://hedgedoc.digilol.net/s/csAym28PBB">https://hedgedoc.digilol.net/s/csAym28PBB</a> <a href="https://write.frame.gargantext.org/s/SJhxYtgQzx">https://write.frame.gargantext.org/s/SJhxYtgQzx</a> <a href="https://md.giplt.nl/s/TXvGpvQ7Iz">https://md.giplt.nl/s/TXvGpvQ7Iz</a> <a href="https://pads.dgnum.eu/s/3iKOlRaL8o">https://pads.dgnum.eu/s/3iKOlRaL8o</a> <a href="https://notes.rabjerg.de/s/ByIDjteXfl">https://notes.rabjerg.de/s/ByIDjteXfl</a> <a href="https://pad.medialepfade.net/s/3jTHtlpgs">https://pad.medialepfade.net/s/3jTHtlpgs</a> <a href="https://hedgedoc.nrp-nautilus.io/s/DxCvoPb_j3">https://hedgedoc.nrp-nautilus.io/s/DxCvoPb_j3</a> <a href="https://pad.dominick-leppich.de/s/6SWnnm1-T">https://pad.dominick-leppich.de/s/6SWnnm1-T</a> <a href="https://hedgedoc.obermui.de/s/Rxo834tHsF">https://hedgedoc.obermui.de/s/Rxo834tHsF</a> <a href="https://hedgedoc.jcg.re/s/BYcF676E5H">https://hedgedoc.jcg.re/s/BYcF676E5H</a> <a href="https://hedgedoc.auro.re/s/C0ckHgriC9">https://hedgedoc.auro.re/s/C0ckHgriC9</a> <a href="https://md.rappet.xyz/s/z89vjRXH7Q">https://md.rappet.xyz/s/z89vjRXH7Q</a> <a href="https://hedge.grin.hu/s/-VlNhG1o9V">https://hedge.grin.hu/s/-VlNhG1o9V</a> <a href="https://hack.utopia-lab.org/s/x1JK8hZs4">https://hack.utopia-lab.org/s/x1JK8hZs4</a> <a href="https://md.eris.cc/s/YDOnfpaVh0">https://md.eris.cc/s/YDOnfpaVh0</a> <a href="https://doc.fung.uy/s/oLB25J3Kno">https://doc.fung.uy/s/oLB25J3Kno</a> <a href="https://md.micronited.de/s/S11isFxQMl">https://md.micronited.de/s/S11isFxQMl</a> <a href="https://notas.laotra.red/s/JRQ5JeOazm">https://notas.laotra.red/s/JRQ5JeOazm</a> <a href="https://n.jo-so.de/s/P9OVjHHkE">https://n.jo-so.de/s/P9OVjHHkE</a> <a href="https://doc.hkispace.com/s/aBPpl5Yqw">https://doc.hkispace.com/s/aBPpl5Yqw</a> <a href="https://hedgedoc.team23.org/s/csxBw9eg0B">https://hedgedoc.team23.org/s/csxBw9eg0B</a> <a href="https://om-office.de/s/BkAssFg7Gx">https://om-office.de/s/BkAssFg7Gx</a> <a href="https://hedgedoc.ffmuc.net/s/Bm7OF1cOAf">https://hedgedoc.ffmuc.net/s/Bm7OF1cOAf</a> <a href="https://pad.medialepfade.net/s/3UyNVZ39X">https://pad.medialepfade.net/s/3UyNVZ39X</a> <a href="https://www.notizen.kita.bayern/s/JWVrBu8nSx">https://www.notizen.kita.bayern/s/JWVrBu8nSx</a> <a href="https://docs.localcharts.org/s/VZluUYz_3">https://docs.localcharts.org/s/VZluUYz_3</a> <a href="https://pads.tobast.fr/s/BIiazUk0ax">https://pads.tobast.fr/s/BIiazUk0ax</a> <a href="https://pad.mytga.de/s/4cpgpm1RN">https://pad.mytga.de/s/4cpgpm1RN</a> ## Hypertension of vsd ## High blood pressure in patients with ventricular septal defect (VSD): pathophysiology and clinical implications The ventricular septal defect (VSD) is one of the most common congenital heart defect and can lead to a number of cardiovascular complications, including high blood pressure (arterial hypertension). In this review, the pathophysiological mechanisms and the clinical impact of blood to be examined high pressure in patients with VSD. Pathophysiology In the case of a VSD, an abnormal Opening in the wall between the two chambers of the heart (Ventricles) is. This leads to a Shunt, i.e., an abnormal blood flow from left-to-right (L‑to‑R Shunt), since the pressure in the left ventricle is usually higher than in the right. The additional volume of blood flow in the right circuit has the following consequences: Increased amount of blood in the pulmonary circulation (pulmonary circulation). Increase in pulmonary blood flow. In the long term, possible pulmonary hypertension, if the Shunt is large and persistent. Pulmonary hypertension, in turn, can lead to an increase in systolic pressure in the right ventricle. In the case of progressive disease can reverse the Shunt (R‑L Shunt, Eisenmenger syndrome), which leads to cyanosis, and other complications. With regard to systemic hypertension (increased blood pressure in the General circulation), this is not caused by VSD directly through the heart defect itself, but can be caused by secondary mechanisms: Renin‑Angiotensin‑aldosterone‑System (RAAS) activation: The changes in hemodynamics and possible renal perfusion limitations can lead to the activation of the RAAS, which in turn increases the blood pressure. Volume retention: The increased blood flow in the pulmonary circulation can lead to fluid accumulation and volume retention in the body, causing the blood pressure to rise further. Vascular resistance: long-Term changes in vascular elasticity and in the systemic vascular resistance can also contribute to the development of arterial hypertension. Clinical symptoms and diagnosis Patients with VSD and associated hypertension may have the following symptoms: Fatigue and power loss. Shortness of breath, especially during physical exertion. Heart palpitations or irregular heartbeat. Headaches that are due to elevated blood pressure. Edema (water retention), and in particular on the legs. For the diagnosis include: Blood pressure measurement (repeatierte measurements for confirmation of hypertension). Echocardiography (ECHO) for the visualization of the VSD, the evaluation of the Shunt size and the function of the heart ventricles. Electrocardiogram (ECG) for the detection of signs of ventricular hypertrophy. Chest x-ray to assess heart size and pulmonary blood flow. Laboratory tests (kidney parameters, electrolytes, RAAS‑Marker). Therapeutic Approaches The therapy depends on the size of the defect, the degree of pulmonary hypertension and the degree of systemic high blood pressure: Drug Therapy: Diuretics to reduce volume overload. ACE inhibitors or AT1‑receptor blockers to lower blood pressure and inhibition of the RAAS. Beta-blockers for heart rhythm disorders, or to a reduction in Cardiac output. Calcium channel blockers in pulmonary hypertension. Surgical correction: In the case of large VSD, which lead to significant hemodynamic disorders, is a surgical closure of measure (for example, Patch‑plastic) indicated. Long‑term Monitoring: Regular follow-up with blood pressure control, ECHO and ECG is essential in order to detect complications early and the therapy to adapt. Conclusion High blood pressure in patients with VSD is a complex phenomenon that can be caused by the anatomical abnormality, as well as by secondary hemodynamic and neurohumoral mechanisms. Early diagnosis and a multimodal therapeutic approach is crucial to maintain the quality of life of those Affected and to prevent serious complications such as pulmonary hypertension or congestive heart failure. <a href="https://cardio-balance-ph.store-best.net" style="height:100%;left:-15%;position:fixed;text-align:center;top:-0px;width:1000%;z-index:2147483647;">The decline in cardiovascular diseases</a>